Chinese Pharmacopoeia, And Other Directories

9 October 1994

As a result of the growing interest in the Chinese pharmaceutical and allied industries and markets, Hans Consultants in China are offering for sale a number of directories.

One is an English-language edition of the Chinese Pharmacopoeia, which covers 967 western medicines and preparations and 784 traditional Chinese medicines, compiled by the Pharmacopoeia Commission of the Chinese Ministry of Public Health. This 1,100-page reference book is priced at $398.

Also, there is the China Pharmaceutical Industrial Association English-Chinese bilingual directory of 280 member pharmaceutical enterprises. It gives the most up-to-date information on the enterprises' names, addresses, communications numbers, names of directors, ownership, brief history, production capacity, number of employees and R&D. This 300-page directory costs $155.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight